BR112019007931A2 - composições antivirais para o tratamento de infecções ligadas ao coronavírus - Google Patents

composições antivirais para o tratamento de infecções ligadas ao coronavírus

Info

Publication number
BR112019007931A2
BR112019007931A2 BR112019007931A BR112019007931A BR112019007931A2 BR 112019007931 A2 BR112019007931 A2 BR 112019007931A2 BR 112019007931 A BR112019007931 A BR 112019007931A BR 112019007931 A BR112019007931 A BR 112019007931A BR 112019007931 A2 BR112019007931 A2 BR 112019007931A2
Authority
BR
Brazil
Prior art keywords
treatment
coronavirus
related infections
antiviral compositions
antiviral
Prior art date
Application number
BR112019007931A
Other languages
English (en)
Inventor
Proust Anaïs
Rosa-Calatrava Manuel
Terrier Olivier
Moules Vincent
Original Assignee
Centre Nat Rech Scient
Inst Nat Sante Rech Med
Univ Claude Bernard Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inst Nat Sante Rech Med, Univ Claude Bernard Lyon filed Critical Centre Nat Rech Scient
Publication of BR112019007931A2 publication Critical patent/BR112019007931A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere a uma composição farmacêutica ou veterinária para a sua utilização na prevenção e/ou tratamento de uma infecção por coronavírus mers-cov (síndrome respiratória do oriente médio), caracterizada por compreender, em um carreador farmacêutico adequado, pelo menos um composto escolhido de apigenina e berberina.
BR112019007931A 2016-10-21 2017-10-20 composições antivirais para o tratamento de infecções ligadas ao coronavírus BR112019007931A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1660223A FR3057773B1 (fr) 2016-10-21 2016-10-21 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
PCT/FR2017/052889 WO2018073549A1 (fr) 2016-10-21 2017-10-20 Compositions antivirales pour le traitement des infections liees aux coronavirus

Publications (1)

Publication Number Publication Date
BR112019007931A2 true BR112019007931A2 (pt) 2019-07-02

Family

ID=57861033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007931A BR112019007931A2 (pt) 2016-10-21 2017-10-20 composições antivirais para o tratamento de infecções ligadas ao coronavírus

Country Status (14)

Country Link
US (1) US11510896B2 (pt)
EP (1) EP3528835B1 (pt)
JP (1) JP7005611B2 (pt)
KR (1) KR102265798B1 (pt)
CN (1) CN110035767B (pt)
BR (1) BR112019007931A2 (pt)
CA (1) CA3041165A1 (pt)
FR (1) FR3057773B1 (pt)
IL (1) IL266119B (pt)
RU (1) RU2753534C2 (pt)
TN (1) TN2019000126A1 (pt)
TW (1) TWI787210B (pt)
WO (1) WO2018073549A1 (pt)
ZA (1) ZA201903161B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108721271B (zh) * 2018-05-04 2022-04-01 中国疾病预防控制中心病毒病预防控制所 莫能霉素在制备广谱抗冠状病毒药物中的应用
WO2020111869A1 (ko) * 2018-11-30 2020-06-04 주식회사 하임바이오 산증 유발 약제의 병용 투여용 약학조성물
CN114984009A (zh) * 2019-08-31 2022-09-02 广州自远生物科技有限公司 异喹啉类化合物制备抗冠状病毒产品中的用途
JP2023520979A (ja) * 2020-03-08 2023-05-23 ヒューマニゲン インコーポレイティッド コロナウイルス感染症及び生じる炎症誘導性肺損傷を治療するための方法
FR3108033B1 (fr) 2020-03-10 2023-04-21 Univ Claude Bernard Lyon COMPOSES ANTIVIRAUX ET LEURS COMBINAISONS POUR TRAITER L’INFECTION VIRALE PAR LE SARS-CoV-2
CN113384688A (zh) * 2020-03-11 2021-09-14 上海上药第一生化药业有限公司 一种糜蛋白酶在抗冠状病毒中的应用
WO2021207176A1 (en) * 2020-04-06 2021-10-14 Humanetics Corporation Genistein treatment of inflammatory pulmonary injury
AU2021261049A1 (en) * 2020-04-24 2022-11-10 Topelia Aust Limited Products of manufacture and methods for treating, ameliorating or preventing microbial infections
WO2021224914A1 (en) * 2020-05-04 2021-11-11 Prilenia Neurotherapeutics Ltd. Treatment of viral infection, disease or disorder using a selective s1r agonist
DE102020002742A1 (de) 2020-05-07 2021-11-11 Mathias Ebert Florviamin
WO2022104153A2 (en) * 2020-11-12 2022-05-19 Beth Israel Deaconess Medical Center, Inc. Compounds and methods for treating viral infections
CN112220808A (zh) * 2020-11-18 2021-01-15 上海中医药大学 一种麻黄提取物及其活性成分和用途
EP4000606A1 (en) * 2020-11-18 2022-05-25 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Compounds for coronavirus infection treatment and/or prevention
WO2022115654A1 (en) * 2020-11-30 2022-06-02 Academia Sinica Methods for treating sars-cov-2 infection
KR20220102595A (ko) * 2021-01-13 2022-07-20 에이비온 주식회사 잠재적인 호흡기 바이러스 감염 개체에 인터페론-베타를 투여하는 것을 포함하는 호흡기 바이러스에 대한 예방적 투여 방법
WO2022192093A1 (en) * 2021-03-08 2022-09-15 Humanigen, Inc. Methods for treating coronavirus infection and resulting inflammation-induced lung injury
CN113230254B (zh) * 2021-05-27 2022-08-23 广州市朝利良生物科技有限公司 一种抗SARS-CoV-2的药物及应用
CN113975265A (zh) * 2021-12-13 2022-01-28 天津中医药大学 芹菜素在制备预防和/或治疗SARS-CoV-2感染的药物中的用途
CN114874174B (zh) * 2022-02-25 2023-09-22 云南民族大学 具有抗乙肝病毒和冠状病毒作用的苯并二氢吡喃类化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995027A (en) 1975-06-04 1976-11-30 Eli Lilly And Company Anti-viral method in animals
CN1089851A (zh) * 1993-01-20 1994-07-27 曹青春 防治感冒喷雾剂及其制备方法
PL203216B1 (pl) * 2000-07-28 2009-09-30 Immupharm Aps Zastosowanie lecznicze hydroksyetylorutozydów, kompozycja farmaceutyczna zawierająca hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺, zestaw zawierający hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺, oraz zastosowanie lecznicze kompozycji farmaceutycznej lub zestawu zawierającego hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺
GB0212405D0 (en) 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
EP1556021B1 (en) * 2002-10-24 2007-12-19 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
US7544712B1 (en) 2003-05-28 2009-06-09 National Health Research Insitutes Treatment of coronavirus infection
CA2640667C (en) 2006-01-30 2013-11-19 Roger C. Cook Three dimensional geometric puzzle
CN101108200A (zh) * 2006-04-21 2008-01-23 朱耕新 繁缕磺酸或硫酸多糖酯总酚苷组合物及其制备方法和抗病毒应用
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
US20130072513A1 (en) * 2009-04-22 2013-03-21 James Spencer COMBINATIONS OF BERBERINE, ARTEMISININ, Loperamide AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES
CN101829113B (zh) * 2009-07-14 2012-12-12 武汉大学 黄连素在治疗或预防流感病毒药物中的应用
FR2953410B1 (fr) 2009-12-09 2012-02-24 Univ Claude Bernard Lyon Compositions antivirales pharmaceutiques ou veterinaires
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
FR2967072B1 (fr) * 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
WO2013185126A2 (en) * 2012-06-08 2013-12-12 Lankenau Institute For Medical Research Compositions and methods for tight junction modulation
WO2015157223A1 (en) * 2014-04-07 2015-10-15 University Of Maryland, Baltimore Methods of treating coronavirus infection
WO2016013793A1 (ko) 2014-07-24 2016-01-28 고려대학교 산학협력단 감마 허피스바이러스 감염의 개선 및 치료에 사용하기 위한 아까시나무 추출물, 아카세틴 및 아피제닌의 용도
FR3025107B1 (fr) * 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
CN104225026B (zh) 2014-09-23 2016-03-16 辽宁恩群蟾蜍科技有限公司 用于治疗急慢性咽喉炎、上呼吸道感染、病毒性感染药物
FR3033701B1 (fr) 2015-03-19 2021-01-15 Univ Claude Bernard Lyon Nouvelles compositions antivirales pour le traitement de la grippe
CN107850941A (zh) 2015-06-26 2018-03-27 沙特基础工业全球技术公司 用于电子设备中的触觉反馈的机电致动器
FR3049861A1 (fr) 2016-04-07 2017-10-13 Univ Claude Bernard Lyon Nouvelles compositions antivirales pour le traitement de la grippe

Also Published As

Publication number Publication date
CN110035767A (zh) 2019-07-19
US20190307722A1 (en) 2019-10-10
CN110035767B (zh) 2021-08-31
KR102265798B1 (ko) 2021-06-15
JP2019535667A (ja) 2019-12-12
TWI787210B (zh) 2022-12-21
WO2018073549A1 (fr) 2018-04-26
KR20190071765A (ko) 2019-06-24
ZA201903161B (en) 2020-09-30
TN2019000126A1 (fr) 2020-10-05
US11510896B2 (en) 2022-11-29
RU2019114665A (ru) 2020-11-23
TW201817430A (zh) 2018-05-16
EP3528835B1 (fr) 2021-03-03
FR3057773A1 (fr) 2018-04-27
RU2753534C2 (ru) 2021-08-17
FR3057773B1 (fr) 2020-06-19
EP3528835A1 (fr) 2019-08-28
IL266119B (en) 2021-01-31
JP7005611B2 (ja) 2022-01-27
RU2019114665A3 (pt) 2021-01-20
CA3041165A1 (fr) 2018-04-26
IL266119A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
BR112019007931A2 (pt) composições antivirais para o tratamento de infecções ligadas ao coronavírus
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112019006642A2 (pt) antagonistas multiméricos de e-selectina altamente potentes
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
IN2013MU01749A (pt)
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112017023263A2 (pt) compostos antivirais rsv de pirazolo e triazolopirimidina
BR112015030389A2 (pt) uso de i) uma fonte de proteína, ii) um prebiótico e iii) um probiótico para a fabricação de uma composição nutricional para o tratamento ou a prevenção de infecção em um indivíduo alérgico
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
BR112017028449A2 (pt) polipeptídeos rsv f pré-fusão solúveis estabilizados
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
BR112017019845A2 (pt) novas composições antivirais para o tratamento da gripe
BR112019002734A2 (pt) tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
BR112018014794A2 (pt) pirimidinas substituídas com arila para uso em infecção pelo vírus influenza
CL2018003383A1 (es) Proteínas f de prefusión del vrs estabilizadas.
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112016012599A2 (pt) composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112016022722B8 (pt) Composto, composição farmacêutica que o comprende e uso do mesmo
BR112017006005A2 (pt) composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]